(1R,5S,6S,7R)-5,7-dimethyl-2-azabicyclo[4.1.0]hept-2-en-3-amine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吖庚因类
• 英文名称: (1R,5S,6S,7R)-5,7-dimethyl-2-azabicyclo[4.1.0]hept-2-en-3-amine
• 化学式: C₈H₁₄N₂
• 分子量: 138.213
• InChiKey: ALTBCVLSYAPCBD-UGSJSWHKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  38.4
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  methyl 3-(R)-methyl-5-hydroxypentanoate 在 palladium on activated charcoal sodium hydroxide 、 正丁基锂 、 三氟化硼乙醚 、 potassium tert-butylate 、 triethyloxonium fluoroborate 、 三氧化硫吡啶 、 甲基三辛基氯化铵 、 对甲苯磺酸 、 乙酸乙酯 、 三乙胺 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 二甲基亚砜 、 苯甲醚 、 甲苯 为溶剂， 反应 56.5h， 生成 (1R,5S,6S,7R)-5,7-dimethyl-2-azabicyclo[4.1.0]hept-2-en-3-amine
  参考文献：
  名称：

  Design and Synthesis of Orally Bioavailable Inhibitors of Inducible Nitric Oxide Synthase. Identification of 2-Azabicyclo[4.1.0]heptan-3-imines

  摘要：

  Further chemical modification of 2-iminopiperidines fused to cyclopropane rings was performed. Optically active isomers 2 and 13 were synthesized and their biological activity was evaluated. Compound 2 exhibited greater potency and more isoform selectivity than enantiomer 13 in the iNOS inhibition assay. One of the gem-chlorines on the fused cyclopropane moiety of 2 was eliminated to produce 3, which showed reduced potency for iNOS inhibition, as well as 4 with an increased potency. The isoform selectivity of 4 was also much higher than that of 3. This was also true for the corresponding methyl derivatives 6-9. The structure-activity relationship (SAR) study and computer aided docking study of the most optimized structure 4 with human iNOS will also be reported. (C) 2003 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(03)00034-8

文献信息

• Compounds for treating inflammatory disorders, demyelinating disdorders and cancers
  申请人：Ajami M. Alfred

  公开号：US20080108641A1

  公开（公告）日：2008-05-08

  Compounds of formula (I) and a method of treating a patient suffering from an inflammatory and/or demyelinating disorders, comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. Definitions for the variables are provided therein.

  公式（I）的化合物及治疗患有炎症和/或脱髓鞘性疾病的患者的方法，包括向该患者施用公式（I）的化合物或其药学上可接受的盐的治疗有效量。其中提供了变量的定义。
• Indazole Compounds for Treating Inflammatory Disorders, Demyelinating Disorders and Cancers
  申请人：Ajami Alfred M.

  公开号：US20100292231A1

  公开（公告）日：2010-11-18

  Compounds of formula (I) or formula (Ia) and a method of treating a patient suffering from certain inflammatory disorders, demyelinating disorders, FLT3-mediated disorders, CSF-1R-mediated disorders, cancers and leukemias, comprising administering to said patient a therapeutically effective amount of a compound of formula (I) or formula (Ia) or a pharmaceutically acceptable salt thereof. Definitions for the variables are provided herein.

  本发明涉及具有公式（I）或公式（Ia）的化合物以及治疗患有某些炎症性疾病、脱髓鞘性疾病、FLT3介导的疾病、CSF-1R介导的疾病、癌症和白血病的患者的方法，包括向该患者施用公式（I）或公式（Ia）的化合物或其药学上可接受的盐的治疗有效量。变量的定义在此提供。
• Compounds and methods for the treatment of asthma
  申请人：Pearson James

  公开号：US20070249644A1

  公开（公告）日：2007-10-25

  Compounds and methods for the treatment of asthma are disclosed. The methods involve mast cell stabilization together with selective inhibition of iNOS. The compounds are combinations of a mast cell inhibiting moiety and an inhibitor of iNOS. An example is:
• Selective Inhibitors Of i-NOS For Use Against Viral Infection
  申请人：UCL Business PLC

  公开号：US20180214430A1

  公开（公告）日：2018-08-02

  The present invention concerns compounds for use in the prevention of viral replication and/or the prevention or treatment of a viral infection, wherein the compounds are selective inhibitors of inducible nitric oxide synthase, and methods of preventing viral replication and/or preventing or treating viral infections in a subject comprising administering a prophylactically or therapeutically effective amount of the compounds.
• US8088935B2
  申请人：——

  公开号：US8088935B2

  公开（公告）日：2012-01-03